Clinical and nonclinical data to be presented for EnteraGam® (Serum-derived bovine immunoglobulin/protein isolate, SBI) at DDW 2016.

Entera Health, Inc. today announces four poster presentations that will take place at the Digestive Disease Week 2016 Annual Meeting in San Diego, CA, from Saturday, May 21 – Tuesday, May 24, 2016.

Monday, May 23 – Poster Session. 9:30am – 4:00pm (Authors present Noon – 2:00pm)
Poster Mo1667: The Effects of Dietary Protein and Serum-Derived Bovine Immunoglobulin/Protein Isolate in a Murine Model of Clostridium difficile Infection.
Christopher J. Detzel, PhD, Entera Health, Ankeny, IA.

Tuesday, May 24 – Poster Session. 9:30am – 4:00pm (Authors present Noon – 2:00pm)
Poster Tu1791: An Open-Label Study Evaluating Symptoms and Potential Mechanisms of Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
Michael Camilleri, MD, Mayo Clinic, Rochester, MN.

Poster Tu1853: Serum-Derived Bovine Immunoglobulin/Protein Isolate Stimulates Cell Migration following Damage in an Intestinal Epithelium Cell Culture Model.
Christopher J. Detzel, PhD, Entera Health, Ankeny, IA.

Poster Tu1394: Management of Fecal Incontinence in Patients Administered a Medical Food: Serum-Derived Bovine Immunoglobulin/Protein Isolate
Kelly Gilmore, MD, Colon & Rectal Clinic Pa, Houston, TX

In addition, representatives from Entera Health will be available at booth #227 to discuss EnteraGam®.

About EnteraGam®

EnteraGam® is a prescription medical food product intended to provide for distinctive nutritional requirements that are unique for the clinical dietary management of specific intestinal disorders [e.g., in irritable bowel syndrome with diarrhea (IBS-D), inflammatory bowel disease (IBD), and HIV-associated enteropathy]. EnteraGam® is required to be used under physician supervision as part of ongoing medical care for a specific condition or disease. EnteraGam® is also indicated for the clinical dietary management of enteropathy in patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients. For full prescribing information, please visit the product website at http://enteragam.com/.

Important Safety Information

EnteraGam® is a specially formulated protein source for the management of intestinal disorders. The product has been extremely well tolerated for up to a year in HIV patients and up to 8 months in infants. The major side effects in clinical trials (2-5%) have included mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam® is contraindicated for patients with a hypersensitivity (allergy) to beef, or any components in EnteraGam®. Therefore, patients who have an allergy to beef or any component of EnteraGam® should not take this product. EnteraGam® has not been studied in pregnant or nursing women. The choice to administer EnteraGam® for patients who are pregnant or nursing is at the clinical discretion of the prescribing physician. Medical foods like EnteraGam® are required by FDA regulations to be dosed and monitored by physicians as part of ongoing care for patients with chronic conditions or diseases.

About Entera Health, Inc.

Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. The staff's passion is to help people thrive through healthier living. The staff's motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Learn more at http://www.enterahealth.com/.

For information, please contact:
Aage Lauridsen, Chief Executive Officer

View Press Release Online

Contact Us